|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Antithrombotics - Reaching The Untreated Prophylaxis Market
Datamonitor, April 2007, Pages: 257
Novel oral anticoagulants and antiplatelet agents will have a profound impact on the antithrombotics market.
We expect Bayers rivaroxaban and Sankyo/Eli Lillys prasugrel to achieve blockbuster status.
Parenteral anticoagulants are not expected to be large revenue generators, due to low clinical unmet need in this market segment and strong competition from current gold standard agents.
Scope of this title:
Event-driven sales projections for 2007-16 for key late-stage developmental antithrombotics in the seven major markets
Commercial analysis of late-stage developmental compounds in terms of their ability to satisfy unmet clinical needs
An overview of the antithrombotics R&D pipeline with a comprehensive assessment of all classes in development
Analysis of the potential for developmental antithrombotics with respect to the patient populations for which they are indicated
Highlights of this title:
Following the abrupt withdrawal of AstraZenecas Exanta in February 2006, Bayer Healthcares rivaroxaban and Boehringer Ingelheims Rendix are well positioned to profit from patients switching from warfarin, and market growth obtained by recruiting the previously untreated population. The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents will be genericized within our forecast period. Consequently, pipeline agents are expected to become significant drivers in the market. Acute Coronary Syndrome is usually the first indication for which novel anticoagulants are approved; this is a quick route to market, while drug companies then prepare to launch their products in more lucrative, chronic treatment markets.
Reasons to order your copy:
Understand the factors that will drive the success of next-generation antithrombotics
Overcome the barriers to entry generated by lifecycle strategies of key players in the market
Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs
Customers who bought this item also bought
Pipeline Insight: Antithrombotics - Anticoagulants And Antiplatelets Have Blockbuster Potential
Commercial Insight: Antithrombotics - Market Expands as Disease Management Focuses on Prevention
Pipeline Insight: Antithrombotics - Entering the Era of Exanta
Anticoagulants - A Global Market Review
Drug Eluting Stent (DES) Clinical Trial Analysis
Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need
Pharmacogenomics for Clinical Use and in Drug Development
Interventional Cardiology Clinical Trial Analysis
Pipeline Insight: Dyslipidemia - Pipeline Agents Unlikely To Rejuvenate The Market
Antibody drug conjugates for cancer treatment: Clinical Trial Pipeline
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Pipeline perspectives: Peripheral artery disease Poor disease awareness hinders new agents
|
|
|
|
